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Objective: Our objective was to test the effects of exogenous L-aspartate and 
L-glutamate on myocardial energy metabolism during ischemia-reperfu- 
sion. Methods: Phosphorus 31-magnetic resonance spectroscopy was used 
to observe cellular energetics and intracellular pH in isolated pig hearts 
perfused with blood (group A, n = 8) or blood enriched with 13 mmol/L 
each of L-aspartate and L-glutamate (group B, n = 6). The hearts were 
subjected to 30 minutes of total normothermic ischemia and then reper, 
fused for 40 minutes. Two hearts from each group were inotropically 
stimulated by titration with calcium after normokalemic reperfusion. Left 
ventricular function was measured with the use of a compliant balloon and 
oxygen consumption was calculated. Results: Magnetic resonance spectroscopy 
showed no decrease in the rate of energy decline during ischemia for group B 
versus group A. No significant differences were observed between the two 
groups in terms of myocardial function, oxygen consumption, or the rate or 
extent of high-energy phosphate recovery after normokalemic reperfusion or 
inotropic stimulation. Inotropic stimulation of postischemic hearts, however, 
led to dramatic improvement in myocardial function in both groups (p < 0.05 
for all parameters) and significant improvement in oxygen consumption (p = 
0.01). Conclusions: In a normal, isolated, blood-perfused pig heart subjected to 
30 minutes of total normothermic schemia, (1) enrichment of the perfusate 
with aspartate/glutamate before and after ischemia ffects neither myocardial 
energy metabolism during ischemia-reperfusion nor postischemic recovery of 
myocardial function or oxygen consumption and (2) inotropic stimulation can 
recruit significant postischemic function and sufficient aerobic respiration to 
support it, irrespective of aspartate/glutamate enrichment. (J Thorac Cardio- 
vasc Surg 1997;113:1068-80) 
S ince the introduction of substrate nhancement by Lazar and coworkers 1'2 in 1980, the benefits 
of L-aspartate and L-glutamate in cardioplegic solu- 
tions have been controversial. Nevertheless, aspar- 
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tate/glutamate-enriched blood cardioplegic solu- 
tions are used during elective and emergency car- 
diac operations, 3-5 with possible potential for use 
during cardiac harvesting 6 and neonatal cardiac 
surgery. 7 
We have used phosphorus 31 (31p) magnetic 
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resonance (MR) spectroscopy to investigate the 
effects of exogenous aspartate/glutamate on myocar- 
dial adenosine triphosphate (ATP), phosphocre- 
atine (PCr), inorganic phosphate (Pi), and intracel- 
lular pH in isolated pig hearts subjected to 30 
minutes of total normothermic ischemia and 40 
minutes of reperfusion. 
Materials and methods 
This study was performed in accordance with Canadian 
Council on Animal Care guidelines and approved by the 
Animal Care Committee at the Institute for Biodiagnos- 
tics. 
Solutions. St. Thomas' Hospital II solution (used to 
arrest hearts during isolation) contained (in millimoles 
per liter) NaC1 100, NaHCO3 25, KCI 26, MgCle 16, and 
CaC12 1.2; the pH was adjusted to 7.4 by HC1. Modified 
Krebs-Henseleit solution (for topical hypothermia nd 
hemodilution) for group A (the control group) contained 
(in millimoles per liter) NaC1 118, MgSO 4 1.2, NaH2PO 4 
1.2, Na 2 ethylenediaminetetraacetic acid 0.5, D-glucose 11, 
CaCI 2 1.75, NaHCO3 25, and bovine serum albumin 5 
gm/L. For group B (aspartate/glutamate) he Krebs- 
Henseleit NaC1 content was lowered to 25 mmol/L. 
Heart isolation. The isolated, blood-perfused pig heart 
preparation has been described in detail previously, s 
Domestic pigs (40 to 55 kg) were acclimatized for 2 weeks, 
fasted overnight, and premedicated with an intramuscular 
injection of ketamine hydrochloride (25 mg/kg), midazo- 
lain (400/xg/kg), and atropine sulfate (0.05 mg/kg). Sur- 
gical anesthesia was induced and maintained with isoflu- 
rane (1.5% to 2.0%) in 50% oxygen (in air). After a 
median thoracotomy, the hearts were isolated and ar- 
rested with cold St. Thomas' Hospital II solution. Cold 
Krebs-Henseleit solution was used for topical hypother- 
mia in the cheSt. After excision, the hearts were fitted with 
a compliant latex balloon (unstressed volume >50 ml) in 
the left ventricle (LV) and a 1.0 ml round-bottom flask 
containing phenyl phosphonic acid, a 31P-MR intensity 
reference, in the right ventricle. A catheter was then 
loosely placed inside the coronary sinus (for collection of 
venous blood) and secured to the wall of the right atrium. 
Blood perfusate preparation. After heart excision, 
blood collecting in the chest was removed by suction and 
Krebs-Henseleit solution was used to adjust the hemato- 
erit value to 20% to 25% (normal pig blood hematocrit 
value is about 30%). In both groups, KC1 was omitted 
from the Krebs-Henseleit to compensate for any rise in 
[K +] from residual mixing of cardioplegie solution with 
the blood during cardioplegic infusion. In group B, low- 
NaC1 Krebs-Henseleit solution was used to lower the total 
[Na +] below 120 mmol/L to allow for addition of 13 
mmol/L each of monosodium aspartate and monosodium 
glutamate (from 1.0 molar stock solution). The final [Na +] 
was adjusted to 140 + 5 mmol/L. The final [K +] was 
adjusted to 4.5 _+ 0.5 mmol/L. The osmolarity of the 
prepared perfusate was similar in all experiments and 
comparable with that of the pig's own blood (270 to 280 
mOsm/L). 
Perfusion system. The perfusion system was designed 
to minimize prime volume (<400 ml). Blood was pumped 
from the reservoir with the aid of a Cobe Precision Blood 
Pump (Cobe Laboratories, Inc., Lakewood, Colo.) 
through a hollow-fiber oxygenator (Capiox 308, Terumo 
Corp., Tokyo, Japan) followed by a 20 txm arterial blood 
filter (D735, Dideco, Mirandola, Italy). The arterial ine 
entered the Faraday cage housing the MR magnet 
through a special radiofrequency filter and connected to 
the brachi0cephalic artery cannula. Venous blood was 
collected at the bottom of the MR probe container and 
returned to the reservoir by suction. The system allowed 
blood to recirculate independently of the arterial ine, to 
prevent excessive settling or clotting during periods of 
ischemia. Anticoagulation was maintained by an addi- 
tional bolus of heparin (5000 IU) every hour. Arterial 
blood temperature was maintained at 37 ° C and blood gas 
partial pressures as follows: oxygen tension greater than 
200 mm Hg and carbon dioxide tension between 35 and 45 
mm Hg. 
Heart perfusion. Hearts were perfused through the 
brachiocephalic artery cannula, with the subclavian artery 
cannula initially being used to remove air from the filling 
aorta. The subclavian artery cannula and the LV balloon 
were then connected to pressure transducers (Cobe), 
which were connected to a multichannel polygraph re- 
corder (Gould, Valley View, Ohio). The arterial flow was 
increased gradually over a 5-minute period and adjusted 
to maintain the perfusion pressure at 60 mm Hg until 
initiation of data acquisition, after which constant flow 
rate was maintained (about 1.0 to 1.5 ml/gm heart tissue). 
During initial warming, the hearts were defibrillated as 
required. Once stable, the heart preparation was placed 
inside the MR probe and inserted into the bore of the MR 
magnet: The LV balloon was gradually filled with filtered 
water to achieve a stable diastolic pressure of 0 to 5 mm 
Hg, after which the balloon volume remained constant. 
Experimental protocol. Control hearts (group A, n = 
8) were perfused with blood without added substrate. 
Aspartate/glutamate hearts (group B, n = 6) were per- 
fused with blood enriched with 13 mmol/L each of L- 
aspartate and L-glutamate (dose commonly suggested to 
be beneficial experimentally 9' lo and clinicall3?'5). All 
hearts were perfused for 20 minutes (control perfusion), 
subjected to 30 minutes of total normothermic schemia 
(heart temperature decreased uring ischemia to 32 ° to 
35 ° C), and then reperfused for 40 minutes with the 
respective perfusate used for each group (stage I, Fig. 1). 
To assess possibl e causes for the observed contractile 
dysfunction, we subjected two hearts from each group to 
inotropic stimulation with calcium after stage I reperfu- 
sion. The perfusate [Ca + +] was gradually increased (over 
20 minutes) until myocardial function reached a plateau. 
Heart function was allowed to stabilize for 10 minutes and 
data were collected (stage II) for an additional 10 minutes 
(total 40 minutes). 
Data acquisition. Once the intraventricular balloon 
had been filled, MR magnet shim values were adjusted 
where necessary, after which continuous acquisition of 
31p-MR spectra was initiated. Functional data from the 
LV balloon were collected continuously throughout the 
protocols. Arterial and venous (from coronary sinus) 
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Group A (control): blood without added substrate 
Group B (asp/glu): blood + 13 mmol/L each of asp and glu 
Control Tota l  Reperfusion High C~ + Perfusion 
Perfusion Ischemia (Stage I) (Stage II) 
20 rain 30 rain 40 rain 40 min 
Fig. 1. Outline of experimental protocols. Asp, Aspartate; glu, glutamate. 
blood samples were taken every 10 minutes to measure 
myocardial oxygen consumption (MV02). At the end of 
each protocol, LV biopsy samples were taken for quanti- 
fication of energy metabolites by high performance liquid 
chromatography. A piece of LV tissue was taken to 
determine the dry/wet weight ratio. 
MR spectroscopy methods. MR spectroscopy was per- 
formed in a 40 cm horizontal bore magnet at 7.0-tesla with 
the use of a Bruker Biospec spectrometer (Bruker, 
Karlsruhe, Germany). The heart was suspended inside a 
home-built MR probe consisting of a radiofrequency oil 
surrounding a glass container. After the coil had been 
tuned and the 1H signal used to optimize the magnetic 
field homogeneity, the coil was switched to a frequency of 
121.47 MHz for acquisition of 3~p spectra. Free induction 
decay signals were obtained using 2 K data points and a 
sweep width of 12 KHz. Single radiofrequency pulses were 
used with a pulse length and repetition time of 80 t~sec 
and 2 seconds, respectively. Sixty free induction decay 
signals were accumulated for each spectrum (2-minute 
time resolution). 
Data analysis. Accumulated free induction decay sig- 
nals were transferred to in-house software (Xprep), Fou- 
rier transformed, and phase and baseline corrected. The 
spectra were subjected to 20 Hz line broadening by 
exponential multiplication of the time function and trans- 
ferred to another in-house analysis software package 
(X-Allfit), where they were fitted with Lorentzian curves 
and quantified using the integrals of the curve. To com- 
pensate for changes in spectral intensity during experi- 
ments, peak integral values for the /3-ATP, PCr, and Pi 
peaks were corrected to the reference (phenyl phosphonie 
acid) peak. The /3 peak was used to quantify ATP. 
Intracellular pH was determined from the relative posi- 
tions of the Pi and PCr peaks. 1~ All data are presented as 
means -+ standard errors of the means. Statistical analyses 
were performed with the use of Microsoft Excel 5.0 and 
Statistica 5.0 (Statsoft, Tulsa, Okla.) software. Student's t 
test and the Mann-Whitney U test were used to compare 
data between groups. The paired Student's t test was used 
to compare data across time within groups. 
Results 
Stage I 
Myocardial energy phosphates 
MR SPECTROSCOPY. Fig. 2 shows representative 
31P-MR spectra from a control heart (group A). The 
spectra show that PCr levels decrease immediately 
on initiation of ischemia, Pi levels increase, and the 
three ATP peaks decrease slightly. In addition, the 
Pi peak shifts upfield (i.e., toward the PCr peak), 
indicating decreased intracellular pH. By the end of 
30 minutes of normothermie ischemia, the PCr peak 
has all but vanished, the Pi peak is very large and 
shifted significantly owing to acidification of the 
medium, and the ATP peaks are significantly re- 
duced in size. These parameters appear to return to 
near normal levels during the first few minutes of 
reperfusion, with the exception of the ATP peaks, 
which show only modest recovery. 
The rate and extent of energetic changes through- 
out ischemia nd reperfusion are similar in the two 
groups (Fig. 3). The only apparent difference be- 
tween the two groups is in levels of Pi during control 
perfusion, which was most likely due to difficulties in 
fitting of the Pi peak created by its overlap with 
peaks arising from phosphomonoesters and phos- 
phodiesters (see Fig. 2). Comparison of ATP, PCr. 
and Pi levels in the two groups indicates that 
aspartate/glutamate enrichment of the perfusate did 
not decrease the rate of energetic decline during 
ischemia or improve energy production upon reper- 
fusion (Table I). 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, 
The ATP and PCr content in LV biopsies, normal- 
ized to total tissue creatine, are similar in the two 
groups (Table II). Using ATP concentrations mea- 
sured by high performance liquid chormatography 
and the initial and final ATP levels from MR 
spectroscopy, the preischemic ATP concentration is 
estimated at 28 -: 3 ~mol/gm and 26 z 1 /~mol/gm 
dry weight for groups A and B. respectively. These 
values are in good agreement with those obtained 
for pig hearts in other studies. 12 
IntraceUularpH. Myocardial intracellular pH dur- 
ing control perfusion averaged 7.22 +_ 0.15 and 
7.30 _+ 0.07 for groups A and B. rspectively. The 
changes in intracellular pH during the protocols are 
shown in Fig. 4 and summarized in Table I. 
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Fig. 2. Representative 31p-MR spectra obtained from a 
blood-perfused pig heart during control perfusion, normo- 
thermic ischemia, and reperfusion. The main resonances are 
from phenyl phosphonic acid (PPA, spectrum intensity ref- 
erence), phosphomonoesters (PME), inorganic phosphate 
(P/), phosphodiesters (PDE), phosphocreatine (PCr), and 
the three phosphate groups (a, /3, and 7) of adenosine 
triphosphate (A TP). The chemical shift is expressed as parts 
per million (PPM) relative to the PCr peak. 
© Control 
Asp/Glu 
0-  
12. 
q.- 
0 
o~ 
500 - -  
400 
300 
200 
4O0- 
35O" 
300- 
250-. 
200- 
150- 
100- 
50- 
0 
120 
100 ¢~ 
(] 8o 
O..c" 
"-- 60' 
O~ 40' 
20" 
0 
0 
~o 4 do ~o 
~o 4 ;o ;o 
I schemia Reper fus ion  
~o 40 do ~o 
T ime (min)  
Fig. 3. Changes in myocardial energy phosphates during 
ischemia-reperfusion. Asp/Glu, Aspartate/glutamate; 
ATP, adenosine triphosphate; PCr, phosphocreatine; Pi, 
inorganic phosphate. Time points represent average me- 
tabolites over a 2-minute period. Data points represent 
means _+ standard errors of the means. 
Myocardial function, oxygen consumption, and 
edema. In all hearts, postischemic recovery of LV 
rate-pressure product (RPP), rate of systolic in- 
crease in ventricular pressure, and rate of diastolic 
decrease in ventricular pressure were poor relative 
to preischemic values (Table III, Fig. 5). As seen in 
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Table I. Changes in myocardial energy phosphates and intracellular pH during ischemia-reperfusion 
Control End of Initial End of 
pet fusion ischemia reperfusion reperfusion 
Group A (control) (n = 8) 
ATP 100 + 3 47 -+ 7 65 ± 4 66 ± 5 
PCr 260 -+ 22 75 -+ 21 298 _+ 23* 318 ± 24* 
Pi 171 ± 21 463 ± 72 182 _+ 21 194 -+ 22 
pHi 7.22 + 0.15 6.33 -+ 0.16 7.18 -+ 0116 7.20 ± 0.07 
Group B (asp@u) (n - 6) 
ATP 100 -+ 1 49 -+ 4 63 -+ 3 65 -+ 4 
PCr 233 ± 13 46 ± 14 310 ± 29* 334 _+ 29* 
Pi 116 ± 7 396 _+ 29 155 ± 8 170 + 9 
pHi 7.30 +_ 0.07 6.44 + 0.19 7.28 _+ 0.11 7.35 ± 0.09 
ATP, Adenosine triphosphate; PCr, phosphocreatine; Pi, inorganic phosphate; pHi, intracellular pH; asp/glu, aspartate/glutamate. ATP, PCr, and Pi are 
expressed as a percentage of initial ATP levels. The values hown are averages over a 10-minute period (6 minutes for pHi) at the indicated stage of the 
protocol. There were no significant differences between groups (p > 0.05). 
*p < 0.01 with respect to control perfusion 
Table II. High-energy metabolites measured by HPLC at the end of stage I reperfusion 
A TP A TP PCr PCr 
(gmol/gm dry wO (% total Cr) (gmol/gm dry wO (% total Cr) 
Group A (control) i7.0 _+ 1.7 10.1 _+ 0.5 106 _+ 6 62.7 -+ 4,5 
Group B (asp/glu) 15.1 + 0.6 9.4 _+ 0.6 104 _+ 7 63.8 + 2.9 
HPLC, High performance liquid chromatography;A TP, adenosine triphosphate; PCr, phosphocreatine; Cr, creatine. Total creatine is equal to the sum of PCr 
and Cr. All data are presented as mean -+ standard error of the mean. There were no significant differences between groups (p > 0;05). 
Table III. Preischemic myocardial function and oxygen consumption 
RPP + dP/dt - dP /dt MVO 2 RPP/MVO 2 
(rnrn Hg/min) (ram Hg/sec) (rnm Hg/sec) (ml 02/100 gin~rain) (ram Hg/mI) 
Group A (control) 10900 _+ 1300 1220 _+ 90 1040 ± 100 5.5 ± 1.4 1100 ± 200 
Group B (asp/glu) 12100 _+ 800 1200 _+ 90 1090 _+ 80 6.3 +_ 1.1 950 +- 90 
RPP, Rate-pressure product; +dP/dt, rate of contraction; -dP/dt, rate of relaxation; MVOz myocardial oxygen consumption~ asp/glu, aspartate/glutamate. All 
data are presented as mean -+ standard error of the mean. There were no significant differences between groups (p > 0.05). 
Table III, aspartate/glutamate did not affect preisch- 
emic MVO2 or the efficiency of conversion of chem- 
ical energy to mechanical function (RPP/MVO2). 
Postischemic recovery of these parameters (Fig. 6) 
was similar in the two groups. 
The total water content at the end of reperfusion 
was similar for the two groups (p = 0.33), with a dry 
weight/wet weight of 16.1% -- 0.4% and 17.6% _+ 
1.3% for groups A and B, respectively. 
Stage II. Tracings of cardiac LV pressure before 
and after titration with Ca ++ show that LV devel- 
oped pressure and the rate of contraction and 
relaxation increased ramatically in stage II (Figs. 7 
and 8). These improvements in myocardial function 
remained relatively stable for the duration of heart 
perfusion. 
Stimulation of the hearts resulted in considerable 
improvements in MVO2 and in the efficiency Of 
conversion of chemical energy to mechanical func- 
tion (RPP/MVO2) (Fig. 9). Although the improve- 
ments in MVO2 and RPP/MVO2 were significant 
(p = 0.03 for both) only for the control group, the 
lack of significance in the aspartate/glutamate group 
is due to the small number of hearts. When the data 
for the control and aspartate/glutamate inotropically 
tested hearts are combined (n = 4), MVO2 (as 
percent of control) is 52 _+ 7 and 86 +_ 7 (p = 0.01), :
whereas RPP/MVO 2 is 59 _+ 7 and 102 _+ 10 (p = 
0.01) for stage I and stage II, respectively. The MR 
spectroscopy spectra showed no change in ATP (66 
_+ 3 vs 66 _+ 2) or Pi (144 _+ 5 vs 150 _+ 5) after 
titration with Ca ++ (Fig. 10). Although PCr levels 
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Fig. 4. Myocardial intracellular pH during ischemia- 
reperfusion as measured from 31p-MR spectra. Each data 
point represents average pH values over a 6-minute pe- 
riod. Datapoints represent means -+ standard errors of the 
means. No statistically significant differences were ob- 
served between the groups (p > 0.05) at any time points. 
Asp/Glu, Aspartate/glutamate. 
decreased from 307 _+ 9 to 273 _+ 8 (p = 0.008), PCr 
levels in stage II were still higher than the preisch- 
emic levels in Table I. These observations are 
consistent with high performance liquid chromatog- 
raphy data from stage I (n = 10) and stage II (n = 
4), showing no change in ATP/total creatine (9.6 _+ 
0.4 vs 10.7 + 0.4, p = 0.14), but a decrease in 
PCr/total creatine (63.4 _+ 1.1 vs 54.8 _+ 2.7, p = 
0.04). Intracellular pH in stage II was maintained at 
7.23 _+ 0.02 (see Table I for control values), negating 
the presence of significant anaerobic metabolism 
during stage II. 
Discussion 
Interpretation of results. Several mechanisms 
have been suggested by which aspartate/glutamate 
may exert beneficial effects on myocardial energet- 
ics. 13 During ischemia, aspartate and glutamate may 
protect myocytes by contributing to anaerobic en- 
ergy production through substrate-level phosphory- 
lation in the citric acid cycle. Through transfer of 
reducing equivalents across the mitochondrial mem- 
brane, aspartate/glutamate may also enhance gly- 
colysis during ischemia by maintaining a supply of 
oxidized nicotinamide adenine dinucleotide in the 
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Fig. 5. Postischemic recovery of LV functional parame- 
ters. Asp/Glu, Aspartate/glutamate; RPP, rate-pressure 
product; +dP/dt, rate of systolic increase in ventricular 
pressure; -dP/dt, rate of diastolic decrease in ventricular 
pressure. Data points represent means + standard errors 
of the means. No statistically significant differences were 
observed between the groups (p > 0.05). 
cytoplasm. Stimulation of glycolysis may also have 
an "oxygen sparing" effect by diverting substrate 
selection away from fatty acids. In addition, during 
ischemia-reperfusion, aspartate/glutamate could 
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Fig. 6. Postischemic recovery of myocardial oxygen con- 
sumption (MVO2) and the efficiency of conversion of 
chemical energy to mechanical work (RPP/MV02). Data 
points represent means -+ standard errors of the means. 
No statistically significant differences were observed be- 
tween the groups (p > 0.05). Asp/Glu, Aspartate/gluta- 
mate. 
stimulate anaplerosis and improve the potential for 
aerobic respiration on reperfusion. 
Our hypothesis was that the mechanisms listed 
herein should improve the energy profile of the 
myocardium during ischemia or reperfusion and 
that continuous observation of high-energy phos- 
phate levels should detect any beneficial effects of 
aspartate/glutamate. Hearts in this study were sub- 
jected to 30 minutes of total normothermic isch- 
emia, resulting in extensive depletion of high-energy 
phosphates and poor recovery of MVO 2 and con- 
tractile function. The severity of ischemia is con- 
firmed by the significant decline in intracellular pH. 
The choice of ischemic insult was such that improve- 
ments in these parameters with aspartate/glutamate 
should have been detected. 
Both groups of hearts showed minimal recovery 
of ATP after ischemia but rapid recovery of PCr 
(see Table I), 14 indicating ood mitochondrial func- 
tion. In addition, significant recovery of myocardial 
function, MVO2, and RPP/MVO2 was observed in 
response to inotropic stimulation, suggesting that 
poor contractile function and MVO 2 during stage [ 
reperfusion were caused by inability of the contrac- 
tile machinery to use the available chemical energy, 
possibly because of a decrease in calcium sensitivity 
of the myofibrils. 12 These results show that low 
postischemic MVO 2 is not necessarily indicative of 
lack of potential for efficient aerobic respiration, 
and decreased myocardial function is not necessarily 
due to energy depletion. Therefore the use of agents 
(such as aspartate/glutamate) intended to improve 
aerobic respiration during reperfusion may be mis- 
guided in instances m which poor contractile func- 
tion or MVO 2 does not represent an inability to 
produce energy. 
The aspartate/glutamate controversy. Numerous 
studies have been conducted on aspartate/glutamate 
enrichment and related topics. Some studies using 
aspartate- and/or glutamate-enriched cardioplegic 
solutions have reported extraordinary bene- 
fits 3, 4, 9, 15, 16 whereas other studies have failed to 
show any benefit whatsoever. 17-19 Yet others ob- 
served only short-lived benefits 2°'21 or attributed 
any benefits to coincident changes in perfusate ionic 
composition. 22 Similar disagreements are found 
among studies using aspartate/glutamate-enriched 
perfusates without cardioplegia. 1' 23-25 Confusion is 
also prevalent on specific issues relating to aspar- 
rate/glutamate. For example. Wiesner and associ- 
ates 26 showed that flow deprivation in dog hearts 
causes reductions in tissue glutamate levels but has 
no effect on aspartate. On the other hand. a study by 
Pisarenko and coworkers 27 correlated postischemic 
recovery of function and energy status in rat hearts 
with maintenance of tissue aspartate, not glutamate, 
an observation that contradicts other studies, includ- 
ing a previous clinical study headed by Pisarenko 
and colleagues. 28
The variability in experimental results relating to 
aspartate/glutamate enrichment may stern largely 
from variations in experimental design. These vari- 
ations include choice of experimental species and 
model, extent and type of ischemic insult, composi- 
tion of the perfusate and reperfusate, concentration 
of amino acid used, temperature, xperimental pa- 
rameters, diagnostic tools, and methods of data 
analysis. Two such factors have contributed signifi- 
cantly to the conflicting results in the literature. First 
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Fig. 7. Representative polygraph tracing showing myocardial function in postischemic hearts before (stage 
I) and after (stage II) inotropic stimulation. The hearts howed ramatic recovery of functional parameters, 
which was sustained for the duration of high Ca ++ perfusion. LV,, Left ventricular. 
130, 
120" 
¢0 
1013" 
.(.~ 
8o" 
6o" 
"T 
m. 40-  
20- 
t ~ Control - Stage I 
r Asp/Glu - Stage I I 
Control - Stage II 
Asp/G u - Stage II 
: : I 
RPP +dP/dt -dP/dt 
Fig. 8. Improvements in postischemic recovery of myo- 
cardial function after inotropic stimulation (stage II). 
Error bars represent standard errors of the means. *p < 
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is the lack of adequate controls in many studies. For 
example, Galifianes and coworkers 22 have shown the 
importance of correcting for coincidental changes in 
ionic composition of cardioplegic solutions when 
using salts of amino acids, a factor overlooked in 
many studies. 2'9, 10, 29 Second is the choice of diag- 
nostic tools and parameters. The failure to provide a 
solution to the aspartate/glutamate controversy may 
be largely due to a lack of adequate tools for direct 
observation of metabolic events throughout an epi- 
sode of ischemia-reperfusion. 
The MR approach. MR spectroscopy allows di- 
rect, continuous observation of metabolic events 
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Fig. 9. Improvements in myocardial oxygen consumption 
(MV02) and the efficiency of conversion of chemical 
energy to mechanical work (RPP/MV02) with inotropic 
stimulation (stage II). Error bars represent s andard errors 
of the means. *p = 0.01 with respect o stage I. Asp/Glu, 
Aspartate/glutamate. 
noninvasively and nondestructively. In this study, we 
used 31p-MR spectroscopy to observe myocardial 
energy metabolism and found that a 13 mmol/L 
concentration of aspartate and glutamate in the 
perfusate did not affect the energetic status of pig 
hearts during ischemia or reperfusion. However, we 
did not gain any insight into the metabolic reactions 
involving aspartate/glutamate. Such information 
could have been provided by carbon 13 (13C) MR 
techniques. 
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13C-MR spectroscopy is well-suited to the study of 
myocardial metabolism, without the need for assum- 
ing metabolic or isotopic steady state. Jessen and 
coworkers 23 recently used 13C isotopomer analysis 
to study the effects of a 5 mmol/L concentration of 
aspartate/glutamate on substrate selection and 
anaplerosis in rat hearts subjected to 25 minutes of 
total normothermic schemia. The results showed no 
effects of aspartate/glutamate on functional recov- 
ery, substrate selection, or anaplerosis. In fact, these 
investigators did not detect any metabolism whatso- 
ever of 13C-labeled aspartate or glutamate. These 
observations are consistent with the results of the 
current study and suggest hat under certain condi- 
tions, exogenous aspartate/glutamate may not be 
able to enter the cell or be incorporated into bio- 
chemical pathways. 
Limitations of the study. The pig heart was cho- 
sen for this study because, with the exception of 
primates, it most closely resembles the human heart. 
Nevertheless, application of the findings to the 
clinical situation requires caution: First. the hearts 
used for this study were initially normal. Diseased 
hearts may have altered metabolism of aspartate/ 
glutamate 3° and thus could respond differently to 
aspartate/glutamate enrichment. Second, an MR- 
compatible modified Langendorff heart was used. It 
is possible that energetic requirements of a working 
model heart would be higher, and thus its response 
to substrate nrichment would be different. Third, 
the MR probe used for this study acquired spectra 
from the whole heart. It is conceiveable that aspar- 
tare/glutamate could have had some effects on spe- 
cific small regions of the heart, but that the effect 
was not large enough to be detected in the whole- 
heart spectra. Fourth, 31P-MR spectroscopy cannot 
distinguish between cytosolic or mitochondrial ATP. 
Aspartate/glutamate may stimulate production of 
ATP by way of substrate-level phosphorylation i
the mitochondria and protect the mitochondria 
without significant effects on overall cellular ener- 
getics. 24 Finally, the extent of functional recovery of 
the hearts may have been limited by the length of 
the reperfusion period (40 minutes). 
The efforts of the following persons have been critical to 
the success of the study. Shelley Germscheid, AHT, and 
Lori Gregorash, AHT, BSc, provided technical assistance, 
and Lori Shoemaker, BSc, carried out biochemical nal- 
yses. All statistical analyses were performed by, or in 
consultation with, Randy Summers, MSc. Our most sin- 
cere appreciation to all of them. 
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Discuss ion 
Dr. Bradley S. Allen (Chicago, Ill.). You have used a 
very elegant model to examine the effects of aspartate and 
glutamate, but I have several problems with your conclu- 
sions. First, most investigators have administered aspar- 
tate and glutamate either as a continuous infusion or as an 
additive to cardioplegic solutions. In addition, no magic 
bullet exists; in other words, if aspartate or glutamate is
simply added to unmodified blood containing high cal- 
cium and low osmolarity, the beneficial effects of amino 
acid supplementation may be negated. Therefore my first 
question is this: Why didn't you use a cardioplegic solu- 
tion, inasmuch as this is where most of the beneficial 
effects of aspartate and glutamate have been demon- 
strated, and do you think this may have changed your 
results? 
Mr. Ghomeshi. Yes, we are aware that many- studies on 
aspartate/glutamate enrichment have used cardioplegic 
solutions. The literature in this area is not only extensive, 
but also very inconclusive, because of significant inconsis- 
tencies from one study to the next. These inconsistencies 
concern the overall effects of aspartate/glutamate, s well 
as the specifics. In fact, there is disagreement over prac- 
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tically everything pertaining to these amino acids, the 
details of which I will not discuss here. 
In this study, we were interested in looking at the 
independent effects of aspartate/glutamate on myocardial 
energy metabolism during ischemia-reperfusion. Thus, to 
avoid the multiplicity of factors that may have caused 
some of the confusion in the literature, we decided to use 
aspartate and glutamate alone, without cardioplegia. Our 
study is not unique in testing the effects of aspartate/ 
glutamate without cardioplegia. Several previous tudies, 
including the original aspartate/glutamate rticle by Dr. 
Lazar in 1980, have used aspartate/glutamate without 
cardioplegia nd have reported benefits. We therefore 
expected that, using this model, we would be able to see 
any beneficial effects from aspartate/glutamate, but we 
were unable to see any effects. 
I do, however, agree that using cardioplegic ischemia 
might have produced ifferent results. The rate of energy 
decline during cardioplegic schemia is significantly lower 
than that which was observed with noncardioplegic isch- 
emia in this study. It is therefore possible that aspartate 
and glutamate could have had very slight effects on 
myocardial energetics that might have been better de- 
tected had we used a cardioplegic solution. 
Dr. Allen. In all of our previous tudies, we always gave 
aspartate/glutamate continuously to maintain a constant 
level. However, you used an isolated heart preparation 
and administered these amino acids only once. Therefore 
the aspartate/glutamate yougave could have been metab- 
olized, resulting in declining levels throughout the study. 
Did you measure levels to determine whether the aspar- 
tate/glutamate concentration remained adequate during 
your measurements? If these levels indeed declined, could 
this not have been partly responsible for your results? 
Mr. Ghomeshi. I agree that it is possible that the levels 
of aspartate/glutamate in the perfusate declined during 
our protocol. However, the volume of perfusate used (2.5 
to 3.0 L) was large compared with the size of the hearts 
(approximately 200 gm), which would make a rapid de- 
cline in aspartate/glutamate concentration unlikely. In 
addition, most studies on aspartate/glutamate gree that 
they have no effects on the myocardium during periods of 
normal perfusion. Therefore it is safe to say that the 
aspartate/glutamate levels in the perfusate should not 
have been affected during the initial perfusion period, 
eliminating this as an explanation for lack of beneficial 
effects during ischemia. It is, however, theoretically pos- 
sible that aspartate/glutamate levels declined during the 
reperfusion period, thus preventing us from seeing bene- 
ficial effects that might otherwise have been observed. 
Dr. Allen. An isolated heart preparation is not the same 
as the clinical setting or an intact experimental model. For 
instance, an isolated heart preparation has no noncoro- 
nary collateral flow. This can yield results different from 
those obtained in the clinical setting. For instance, high 
glucose solutions have been shown to be detrimental when 
given in an isolated heart preparation, whereas in clinical 
cardioplegic solutions they have been shown to be bene- 
ficial. Could the use of your model have explained your 
findings? 
Mr. Ghomeshi. It absolutely could. This study was in an 
isolated heart model, and it was in the pig. Obviously, 
applicability of our conclusions to the clinical setting, or to 
an in vivo model, needs further study and could be very 
limited. 
Dr. Allen. I noticed that you added calcium to obtain a 
steady state in stage II of your experiment. Did the 
different groups require different amounts of calcium? In 
other words, were certain hearts more or less sensitive to 
calcium and were the final ionized calcium levels the 
same? If hearts in different groups had different responses 
or needed different levels of calcium to achieve the same 
response, they may have indeed been different. 
Mr. Ghomeshi. Unfortunately, I cannot answer that 
question, because we tested only two hearts per group 
with calcium. Had we expected the results obtained in the 
study, we would have used inotropic testing in all hearts. 
but we did not. I thus cannot comment on what the results 
might have been had we used a full group of inotropic 
stimulation with or without aspartate/glutamate. 
Dr. Allen. Last. the majority of investigations have 
demonstrated increased oxygen uptake during administra- 
tion of aspartate/glutamate cardioplegic solutions, with 
100% recovery of myocardial function, even after an 
ischemic insult. This increased oxygen uptake usually lasts 
for only the first several minutes of cardioplegic adminis- 
tration and then returns to basal require ments. Not only 
did we see this experimentally, but in a recent clinical 
study reported in the Annals of Surgery we saw an in- 
creased oxygen uptake with aspartate/glutamate cardio- 
plegia even in hemodynamically stable patients undergo- 
ing routine coronary surgery. Once again, the increased 
oxygen uptake was back to baseline after several minutes. 
Conversely, you examined your oxygen uptakes after a 
much longer time interval. Did you measure oxygen 
uptake early during the administration of aspartate/gluta- 
mate? If so, did oxygen uptake differ between groups? Did 
you measure the oxygen uptake across the myocardium 
during the first few minutes of reperfusion, or did you only 
look at oxygen uptake at 15 and 25 minutes after reper- 
fusion? 
Mr. Ghomeshi. MVO 2 and functional recovery were 
presented here after 5 minutes, 15 minutes. 25 minutes. 
and 35 minutes of reperfusion. Therefore postischemlc 
MVO 2 was measured relatively early, but not before 5 
minutes of reperfusion. 
Dr. Harold L. Lazar {Boston, Mass,). [Slide] This slide 
shows the oxygen uptake in dog hearts after 45 minutes of 
normothermic schemac arrest in a study that was pre- 
sented before this Association 16 years ago. After aortic 
unclamping, hearts were either kept in the beating state 
on bypass, the so-called unmodified group, or arrested for 
5 minutes with either blood cardioplegia or a glutamate- 
ennched blood cardioplegic solution. 
After aortic unclamping, the unmodified group showed 
the characteristic depression in oxygen uptake that was 
seen in this present study and is indicative of an injured 
postischemic heart. In contrast, both the cardioplegia 
groups howed a significant increase in oxygen uptake, the 
most significant being in the cardioplegia group that was 
supplemented with glutamate. Subsequently, both the 
cardioplegia nd glutamate groups had more complete 
recovery of ATP and both systolic and diastolic function. 
The best recovery was seen in the glutamate group. 
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Since that study, numerous clinical studies have been 
conducted, as you have alluded to, which showed the 
benefits of glutamate in patients with angina, congestive 
heart failure, and as a cardioplegic additive to patients in 
cryogenic shock and after cardiac transplantation. I  view 
of these results, what are the mechanisms that you think 
are responsible for the inability of glutamate and aspar- 
rate to improve both the metabolic and ventricular func- 
tion in your study? Dr. Allen has alluded to the fact that 
you used an isolated preparation with a beating empty 
heart. The energy requirements of an intact working heart 
are much higher than in an isolated preparation. Do you 
think that substrate nhancement would be less likely to 
be effective in your model, which is essentially a nonwork- 
ing reperfusion model? 
Mr. Ghomeshi. The various mechanisms suggested in 
the literature for beneficial effects from aspartate/gluta- 
mate should all lead to the common effect of improving 
myocardial energy levels during either ischemia or reper- 
fusion. These energy levels were measured continuously in
this study, but no effects were observed. Nevertheless, this 
study by itself cannot give information regarding potential 
mechanisms, pecific metabolic pathways, or involvement 
of aspartate and glutamate in these pathways. 
[Slide] In 1993, however, Jessen and coworkers re- 
ported using 13C-MR techniques to provide some insight 
into aspartate/glutamate m tabolism during ischemia- 
reperfusion. 13C-MR spectroscopy allows studying myo- 
cardial metabolic pathways without assumptions of meta- 
bolic or isotopic steady state. Using isolated rat hearts, 25 
minutes of total normothermic schemia, and a 5 mmol/L 
concentration of aspartate/glutamate before and after 
ischemia, these investigators were unable to detect any 
effects on myocardial function, on substrate selection for 
the Krebs cycle, or on anaplerosis (pathways that replen- 
ish Krebs cycle intermediates). In fact, using 13C-labeled 
aspartate or glutamate, they were unable to detect any 
metabolism of these amino acids whatsoever. These re- 
sults, together with those of the current study, suggest that 
at least under certain circumstances, which, as Dr. Lazar 
points out, could be those of using an isolated heart, 
exogenous aspartate and glutamate may not be able to 
enter the cells. Whether that in any way applies to some in 
vivo models or to certain clinical situations, I cannot say. 
The second question was regarding the use of a working 
model. It is true that the working model would use more 
energy than an isolated Langendorff model. Therefore it is 
possible that if we had used a working model, the energy 
consumption would be higher and we might have been 
able to see benefits from aspartate and glutamate. Using 
MR involves technical limitations that make it difficult to 
use what might perhaps be the most relevant model. In 
this case, we used the best model we could find that was 
also relatively simple to do in combination with MR. 
Dr. R. Svedjeholm (LinkOping, Sweden). Inasmuch as 
the heart has a capacity to use a wide range of substrates, 
it implies that under many conditions the addition of extra 
substrates may have little influence on the metabolic and 
hemodynamic function. Therefore it would be surprising 
to find one substrate that in every experimental condition 
improved the metabolic and hemodynamic function of the 
heart. On the other hand, I am sure Mr. Ghomeshi would 
agree that the heart needs substrates to survive and 
produce nergy. In Mr. Ghomeshi's own study, for exam- 
ple, the control hearts were provided substantial mounts 
of amino acids and carbohydrate substrates from normal 
blood. 
Mr. Ghomeshi's study has too many limitations to make 
any conclusions regarding the role of glutamate/aspartate 
for the ischemic and postischemic human heart. These 
include the choice of species, the use of an isolated heart 
preparation, the use of "healthy hearts" not subjected to 
chronic bouts of ischemia, and the study design, to name 
a few. Dr. Kimose from Denmark published a paper in 
1993 demonstrating transient myocardial leakage of glu- 
tamate early after cardioplegic arrest in the isolated pig 
heart. This implies that part of Mr. Ghomeshi's study may 
have been conducted under conditions when uptake of 
glutamate was not to be expected. 
As for species and adaptation to ischemia, several 
investigators, including Mudge, Thomassen, and Pisar- 
enko, have shown that in human beings the single most 
characteristic metabolic feature of chronic ischemic heart 
disease is the increased uptake of glutamate and the 
increased release of alanine. 
However, the most important limitation of Mr. Ghome- 
shi's study is the use of the isolated heart preparation. The 
impact of systemic metabolic and immunologic hanges 
are not accounted for. As for systemic metabolic hanges, 
available data from human beings suggest hat the com- 
bined effects of systemic metabolic hanges and metabolic 
changes in the heart resulting from ischemia make amino 
acids important for postischemic recovery of myocardial 
metabolism. The explanation for this is that Krebs cycle 
intermediates lost during ischemia are replenished pri- 
marily by carbohydrates and amino acids. As a result of 
the systemic metabolic hanges, the uptake of glucose and 
other carbohydrates is impeded and, hence, the relative 
importance of amino acids increased. Moreover, high 
catecholamine l vels in conjunction with elevated free 
fatty acid levels contribute to oxygen wasting and accumu- 
lation of toxic free fatty acid metabolites, thereby provid- 
ing an unfavorable metabolic environment for the isch- 
emic and postischemic heart. Available data from human 
beings undergoing coronary artery bypass grafting proce- 
dures demonstrate hat glutamate uptake precedes recov- 
ery of myocardial metabolism. Furthermore, uptake of 
glutamate seems to be limited by substrate availability, 
that is, arterial levels of glutamate. Accordingly, Pisarenko 
demonstrated nhanced metabolic and hemodynamic re- 
covery by intravenous glutamate infusion in patients with 
heart failure after cardiac operations. In a recent study 
from Link6ping, we were to able emulate these results 
after routine coronary bypass procedures. Moreover, 
Thomassen demonstrated improved myocardial tolerance 
to ischemia in coronary patients during exercise testing 
and pacing by intravenous glutamate administration. Thus 
a number of independent s udies in human beings suggest 
an important role for glutamate during and after ischemia. 
To conclude, I have some questions for Mr. Ghomeshi. 
First, the hearts in the control group were perfused with 
blood that I assume contained substantial amounts of 
substrate, including glutamate. How much glutamate and 
what alternate substrates were used by the control hearts? 
1 0 8 0 Ghomeshi et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
June 1997 
Second, Mr. Ghomeshi uses the term preischemic level, 
although the hearts have been subjected to excision during 
crystalloid cardioplegic arrest. We would consider this a 
postischemic condition; therefore, the degree of recovery 
reported may not be related to the true preischemic level. 
Would Mr. Ghomeshi l ke to comment on this? Third, the 
number of hearts studied was few; for instance, only two 
hearts in each group were subjected to intervention with 
calcium. How did Mr. Ghomeshi arrive at these sample 
sizes? 
Mr. Ghomeshi.  I would like to thank Dr. Svedjeholm 
for his interesting comments on this paper. Dr. Svedje- 
holm's first question is regarding any measurements of
substrate use by control hearts. Unfortunately, the extrac- 
tion of substrates from the perfusate by hearts was not 
measured in our study. The principal purpose of this study 
was to determine whether substrate nrichment of normal 
blood with aspartate and glutamate could provide any 
additional benefits to the ischemic-reperfused hearts. The 
parameters used were myocardial function and oxygen 
consumption but, more important, a direct measurement 
of myocardial high-energy phosphate levels (from MR 
spectroscopy) during the entire protocol. Therefore, in 
the absence of demonstrated beneficial effects of using 
such a direct measure of energy metabolism, measure- 
ments of substrate use by the hearts would be of little 
relevance to the study's purpose. 
Dr. Svedjeholm next questions our use of the term 
preischemic level in presenting the data. I would like to 
clarify that the terms preischemic level and preischemic 
value in this paper efer to measurements taken during the 
period of control perfusion at the start of the experimental 
protocol (see Fig. 1). These terms are used instead of the 
term control solely to prevent confusion with data from 
control hearts (group A). Despite the excision of hearts 
using cold crystalloid cardioplegia, as Dr. Svedjeholm 
points out. these "control" measurements may be different 
from what the true preischemic values may have been. 
Nevertheless. as all hearts were subjected to the same 
excision technique, it is unlikely that the comparative 
functional or metabolic recovery of hearts in any one 
group would change if reported relative to "true" preisch- 
emic levels. The interpretation of results is therefore 
unaffected by our use of terminology. 
The last question concerns the sample sizes in the 
study. The intended sample size for each of groups A 
and B was eight, based on previous tudies using similar 
models. Because of the significant expenses involved. 
experiments in group B were stopped at six. as it 
became clear that aspartate and glutamate had no 
effects whatsoever on any of the parameters studies. As 
for inotropically tested hearts, despite the small num- 
bers, the changes induced with calcium are dramatic 
enough to allow the conservative conclusions made 
based on these data. Clearly, as I am sure Dr. Svedje- 
holm would agree, statistical analysis of any data set 
depends more on the quality and type of the data than 
on the mere number of experiments. 
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